Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Psychiatr Serv. 2014 Oct 31;66(1):15–20. doi: 10.1176/appi.ps.201400055

Rates of Psychiatric Treatment Reported by Patients with Borderline Personality Disorder and Other Personality Disorders over 16 Years of Prospective Follow-up

Mary C Zanarini, Frances R Frankenburg, D Bradford Reich, Lindsey C Conkey, Garrett M Fitzmaurice
PMCID: PMC4283568  NIHMSID: NIHMS597508  PMID: 25270039

Abstract

Objective

The goal of this study was to delineate the course of 16 treatment modalities reported by 290 patients with borderline personality disorder and 72 with other axis II disorders over 16 years of prospective follow-up.

Methods

Treatment use was assessed at baseline and at eight two-year follow-up periods using a semistructured interview of proven reliability and validity.

Results

Patients with borderline personality disorder reported significantly higher rates of use of 12 of the 16 treatment modalities studied. Only individual therapy, intensive individual therapy, couples/family therapy, and ECT were used by roughly the same percentage of patients with borderline personality disorder and those with other axis II disorders. In addition, rates of participation in 13 treatment modalities declined significantly over the first eight years of follow-up for those in both treatment groups. However, the rates of participation in 15 of 16 treatment modalities did not decline significantly over the second eight years of follow-up for those in either study group

Conclusions

The results of this study suggest that rates of treatment use by patients with borderline personality disorder decline significantly over the short and midterm. They also suggest that these rates remain stable or fail to decline further over the longer term.


Clinical experience suggests that patients with borderline personality disorder are more likely to have a history of both outpatient and inpatient psychiatric treatment than patients with other psychiatric diagnoses. Five cross-sectional studies have confirmed this impression (1-5). Two of these studies have also followed their sample of borderline patients and comparison participants longitudinally. In a three-year prospective study from the Collaborative Longitudinal Personality Disorders Study, Bender et al. (6) found that patients with borderline personality disorder were significantly more likely than those with major depression and no serious axis II psychopathology to have been in individual therapy, taken psychotropic medication, had an emergency room visit, and been hospitalized for psychiatric reasons. In a six-year prospective study, Zanarini et al. (7) found that borderline patients who had been hospitalized at the start of this study—the McLean Study of Adult Development—were significantly more likely than those with other axis II disorders to have participated in 11 of the 16 treatment modalities studied. These investigators also found that participation in 12 of the 16 treatment modalities studied declined significantly over time for those in both study groups.

Treatment utilization of this sample was also studied after 10 years of prospective follow-up (8). Only three modalities were studied: individual therapy, standing medication, and psychiatric hospitalization. It was found that over 40% of patients with borderline personality disorder did not use individual therapy or standing medications for at least one two-year follow-up period. However, over 60% of these patients resumed these treatments at a later time period. It was also found that over 80% of patients with borderline personality disorder were not rehospitalized during at least one two-year follow-up period. However, almost half of these patients were later hospitalized for psychiatric reasons.

The current study builds upon these earlier McLean Study of Adult Development studies in three important ways. First, it returns to the inclusive list of treatment modalities assessed in the first of these two longitudinal studies. Second, it adds an additional decade of prospective follow-up to the study of this inclusive list of 16 treatment modalities. Third, it assesses time trends encompassing the first and second eight years of follow-up separately—allowing us to determine the significance of short and midterm declines in use vs. further long-term declines in participation in the 16 treatment modalities studied.

Methods

As noted above, the current study is part of the McLean Study of Adult Development, a multifaceted longitudinal study of the course of borderline personality disorder. The methodology of this study, which was reviewed and approved by the McLean Hospital Institutional Review Board, has been described in detail elsewhere (9). Briefly, all subjects were initially inpatients at McLean Hospital in Belmont, Massachusetts. Each patient was screened to determine that he or she: was between the ages of 18-35; had a known or estimated IQ of 71 or higher; had no history or current symptomatology of schizophrenia, schizoaffective disorder, bipolar I disorder, or an organic condition that could cause serious psychiatric symptoms (e.g., lupus, MS); and was fluent in English.

After the study procedures were explained, written informed consent was obtained. Each patient then met with a masters-level interviewer blind to the patient’s clinical diagnoses for a thorough treatment history as well as diagnostic assessment. Four semistructured interviews were administered: the Background Information Schedule, which assesses lifetime psychiatric treatment history (5); the Structured Clinical Interview for DSM-III-R Axis I Disorders (10); the Revised Diagnostic Interview for Borderlines (11), and the Diagnostic Interview for DSM-III-R Personality Disorders (12). The interrater reliability of the Background Information Schedule was carefully assessed in a sample of 45 personality-disordered patients and was found to be good-excellent (5). As a measure of validity, we compared self-report of treatment history according to this interview with the medical records of 15 patients who had received all of their psychiatric care at McLean Hospital. Convergent validity was also found to be good-excellent (5). In addition, the inter-rater and test-retest reliability of all three diagnostic measures have been found to be good-excellent (13,14).

The psychiatric treatments used by study participants over the years of follow-up were assessed using the treatment section of the Revised Borderline Follow-up Interview (15)—the follow-up analog to the Background Information Schedule. This measure, as well as our diagnostic battery, was readministered every two years over 16 years of prospective follow-up by raters blind to previously collected information. The follow-up interrater reliability (within one generation of follow-up raters) and follow-up longitudinal reliability (from one generation of raters to the next) of these four interviews have also been found to be good-excellent (7,13,14).

The vast majority of our follow-up interviews were conducted within several months of the date of each participant’s last interview. However, two participants who were unavailable for interview at 12 and 14-year waves of data collection provided six years of data at 16-year follow-up. A third participant who was unavailable for interview at 8, 10, 12, and 14-year waves of data collection provided 10 years of data at 16-year follow-up. All told, eight of 2881 interviews (or .3%) assessed a longer time period than our typical two years.

Statistical Analyses

Data on psychiatric treatment were assembled in panel format (i.e., multiple records per patient, with one record for each follow-up period for which data were available). Generalized estimating equations (GEE), appropriately accounting for repeated measures on the same patients, were used to fit loglinear regression models assessing the role of diagnostic group on the prevalence of treatment use over time. Specifically, these analyses modeled the log prevalence as a piecewise-linear function of time, with separate slopes for the change from baseline to 8 year follow-up and for the corresponding change from 8 to 16 year follow-up; the models also included the effect of diagnostic group. Preliminary tests of diagnostic group by time interactions were also conducted to assess whether the pattern of change in prevalence differed by diagnostic group. As there was no evidence of interaction, main effects of diagnostic group and time are reported; results of these analyses yielded an adjusted relative risk ratio (RRR) and 95% confidence interval (95%CI) for diagnostic group and the two time trends. Given the large number of comparisons for the 16 treatment modalities, we applied the Bonferroni correction for multiple comparisons to the analysis of each treatment modality, resulting in the following corrected alpha level: .0031 (.05/16).

Results

The sample and its diagnostic characteristics have been described before (9). Two hundred and ninety patients met both Revised Diagnostic Interview for Borderlines and DSM-III-R criteria for borderline personality disorder and 72 met DSM-III-R criteria for at least one nonborderline axis II disorder (and neither criteria set for borderline personality disorder). Of these 72 comparison participants, three (4%) met DSM-III-R criteria for an odd cluster personality disorder, 24 (33%) met DSM-III-R criteria for an anxious cluster personality disorder, 13 (18%) met DSM-III-R criteria for a nonborderline dramatic cluster personality disorder, and 38 (53%) met DSM-III-R criteria for personality disorder not otherwise specified (which was operationally defined in the Revised Diagnostic Interview for Personality Disorders as meeting all but one of the required number of criteria for at least two of the 13 axis II disorders described in DSM-III-R).

Baseline demographic data have also been reported before (9). Briefly, 279 (77%) of the participants were female and 315 (87%) were white. The average age of the participants was 27 years (SD=6.3), the mean socioeconomic status was 3.3 (SD=1.5) (where 1=highest and 5=lowest), and their mean GAF score was 39.8 (SD=7.8) (indicating major impairment in several areas, such as work or school, family relations, judgment, thinking, or mood).

In terms of continuing participation, which has also been described before (16), 231/264 (88%) of surviving patients with borderline personality disorder (13 died by suicide and 13 died of other causes) were reinterviewed at all eight follow-up waves. A similar rate of participation was found for axis II comparison participants, with 58/70 (83%) of surviving patients in this study group (one died by suicide and one died of other causes) being reassessed at all eight follow-up waves.

Table 1 details the rates of outpatient treatments as well as more intensive treatments, such as psychiatric hospitalizations, reported by those in our study groups over 16 years of prospective follow-up. As can be seen, patients with borderline personality disorder were not significantly more likely to report being in individual therapy, intensive individual therapy, or couples/family therapy than those with other axis II disorders. However, they were significantly more likely to report being in group therapy and self-help groups. They were also significantly more likely to report taking any standing medication, all forms of polypharmacy studied (2-5 standing medications), and all forms of more intensive treatment studied except ECT (day treatment, residential treatment, psychiatric hospitalizations, multiple psychiatric hospitalizations, and hospitalizations lasting 30 days or more). During the first 8 years of follow-up (0-8 years), reported rates of all forms of treatment were found to decline significantly for those in both study groups except taking four or five or more concurrent medications and ECT. Conversely, during the last eight years of follow-up (8-16 years), reported rates of almost all forms of treatment remained relatively flat or stable over time for both study groups; the only exception was the rate of 30 days or more of psychiatric hospitalization, which continued to decline significantly for those in both study groups.

Table 1.

Rates of Psychiatric Treatment Reported by Borderline Patients and Axis II Comparison Subjects over 16 Years of Prospective Follow-up

BL 2 YR FU 4 YR FU 6 YR FU 8 YR FU 10 YR FU 12 YR FU 14 YR FU 16 YR FU RRR
Diagnosis
Time (0-8)
Time (8-16)
95%CI
Diagnosis
Time (0-8)
Time (8-16)
P-value
Diagnosis
Time (0-8)
Time (8-16)
N % N % N % N % N % N % N % N % N %
Outpatient Psychosocial Treatments
Individual Therapy
BPD 279 97 257 93 211 78 197 75 186 73 181 73 167 68 154 65 149 65 1.06
.71
.91
.99-1.14
.66-.76
.84-1.00
NS
<0.001
NS
OPD 62 86 59 88 42 66 40 64 28 45 27 44 36 60 28 48 32 55
Intensive Psychotherapy (>=2 sessions per wk)
BPD 105 36 102 37 63 23 42 16 44 17 40 16 33 14 33 14 30 13 1.78
.40
.86
1.13-2.78
.31-.51
.63-1.16
NS
<0.001
NS
OPD 14 19 13 19 6 9 7 11 4 7 5 8 5 8 4 7 5 9
Group Therapy
BPD 105 36 63 23 46 17 32 12 35 14 24 10 29 12 33 14 17 7 1.78
.29
1.06
1.23-2.59
.22-.39
.71-1.61
.002
<0.001
NS
OPD 13 18 4 6 4 6 4 6 2 3 0 0 3 5 3 5 6 10
Couples/Family Therapy
BPD 112 39 53 19 30 11 22 8 25 10 19 8 19 8 17 7 12 5 1.23
.19
1.07
.87-1.73
.13-.27
.65-1.78
NS
<0.001
NS
OPD 21 29 9 13 6 9 4 6 5 8 4 7 5 8 4 7 5 9
Self-help Groups
BPD 148 51 80 29 68 25 54 21 41 16 36 15 36 15 35 15 34 15 1.86
.31
1.05
1.30-2.65
.24-.41
.77-1.43
.001
<0.001
NS
OPD 23 32 11 16 6 9 8 13 7 11 7 12 6 10 7 12 6 10
Standing Medications
Any Standing Medication
BPD 244 84 237 86 204 76 187 71 180 71 179 72 183 75 172 72 165 71 1.29
.81
1.03
1.13-1.48
.75-.88
.95-1.11
<0.001
<0.001
NS
OPD 44 61 52 78 34 53 34 54 30 48 32 53 35 58 30 51 30 52
Two or More Concurrent Medications
BPD 190 66 176 64 149 55 130 49 134 53 130 52 121 50 119 50 119 52 2.10
.75
1.05
1.60-2.76
.66-.84
.93-1.18
<0.001
<0.001
NS
OPD 18 25 28 42 16 25 12 19 10 16 17 28 17 28 16 27 19 33
Three or More Concurrent Medications
BPD 132 46 116 42 107 40 92 35 91 36 81 33 79 32 82 35 82 36 2.82
.73
1.06
1.89-4.20
.62-.85
.90-1.24
<0.001
<0.001
NS
OPD 9 13 15 22 8 13 5 8 3 5 9 15 10 17 8 14 9 16
Four or More Concurrent Medications
BPD 83 29 62 23 58 22 46 17 55 22 53 21 43 18 51 21 43 19 4.65
.72
1.06
2.54-8.51
.56-.93
.82-1.38
<0.001
NS
NS
OPD 1 1 6 9 5 8 1 2 0 0 3 5 3 5 4 7 4 7
Five or More Concurrent Medications
BPD 52 18 32 12 27 10 25 10 25 10 26 10 19 8 19 8 16 7 8.37
.58
.81
2.89-24.2
.39-.85
.52-1.27
<0.001
NS
NS
OPD 1 1 1 2 2 3 0 0 0 0 1 2 1 2 1 2 0 0
More Intensive Treatments
Day Treatment
BPD 123 42 113 41 62 23 47 18 34 13 27 11 31 13 26 11 18 8 1.92
.28
.63
1.37-2.69
.22-.37
.43-.93
<0.001
<0.001
NS
OPD 14 19 20 30 5 8 4 6 2 3 1 2 3 5 2 3 1 2
Residential Treatment
BPD 107 37 78 28 32 12 26 10 25 10 12 5 16 7 13 6 10 4 3.94
.19
.74
2.25-6.91
.13-.27
.45-1.23
<0.001
<0.001
NS
OPD 7 10 6 9 1 2 1 2 1 2 0 0 0 0 2 3 1 2
Any Psychiatric Hospitalization
BPD 228 79 164 60 97 36 86 33 71 28 72 29 71 29 58 24 55 24 1.80
.31
.99
1.41-2.30
.26-.37
.80-1.21
<0.001
<0.001
NS
OPD 36 50 15 22 9 14 9 14 7 11 2 3 7 12 3 5 5 9
Multiple Hospitalizations
BPD 175 60 11 43 70 26 61 23 45 18 36 15 40 16 34 14 35 15 3.25
.26
.94
2.11-5.00
.20-.33
.70-1.27
<0.001
<0.001
NS
OPD 15 21 7 11 5 8 2 3 3 5 0 0 5 8 1 2 2 4
30 Days or More of Psychiatric Hospitalization
BPD 174 60 95 35 55 21 49 19 19 8 18 7 17 7 10 4 8 4 2.34
.14
.39
1.68-3.27
.11-.19
.22-.69
<0.001
<0.001
.001
OPD 21 29 9 13 2 3 2 3 2 3 0 0 1 2 0 0 0 0
ECT Treatment
BPD 20 7 19 7 11 4 10 4 12 5 8 3 9 4 2 1 4 2 1.60
.54
.43
.81-3.15
.28-1.02
.20-.95
NS
NS
NS
OPD 4 6 4 6 0 0 1 2 2 3 0 0 2 3 2 3 0 0

As these results are complicated, we present two examples from Table 1 so that they can be better understood. As noted above, the rates of reported individual therapy were not significantly different between the diagnostic groups over time. However, there was a significant decline in the rates during the first eight years of follow-up that was the same for those in both study groups; specifically, there was a 29% decline ([1 – .71] × 100%) in the rates from baseline to year eight in both groups. Thereafter, during years 8-16, there was no significant change in the rates in both groups. As also noted above, patients with borderline personality disorder reported significantly higher rates (2.3 times higher) of 30 days or more of psychiatric hospitalization than axis II comparison participants over time. However, the significant declines in the reported rates were the same for those in both diagnostic groups ([1-.14] × 100%=86% decline in years 0-8, followed by [1-.39] × 100%=61% decline in years 8-16.

Discussion

Three main findings have emerged from this study. The first is that patients with borderline personality disorder reported significantly higher rates of use of 12 of the 16 treatment modalities studied—all but individual therapy, intensive individual therapy, couples/family therapy, and ECT. Or looked at another way, all forms of pharmacotherapy and more intensive treatment studied (e.g., psychiatric hospitalizations, day treatment) were reported by a significantly higher percentage of patients with borderline personality disorder than those with other axis II disorders over time. This finding is consistent with our results at study entry (5) and over six years of prospective follow-up (7). It also highlights the consistent severity of borderline psychopathology compared to that of other personality disorders (17). In addition, it is consistent with the higher rates of co-occurring disorders reported by patients with borderline personality disorder than axis II comparison participants over time (18,19).

The second main finding is that rates of participation in 13 treatment modalities declined significantly over the first eight years of follow-up for those in both treatment groups. Only the rates of four or five concurrent medications and ECT remained stable over these eight years. This finding too is consistent with the results we found at six-year follow-up (7).

The third main finding is that the rates of participation in 15 of 16 treatment modalities did not continue to decline significantly over the second eight years of follow-up for those in either study group. Only the rate of hospitalizations of 30 days or more declined significantly from 8-16 years of follow-up for those in both study groups. This is a new finding and an important one with public health significance. It suggests that the cost of treating patients with borderline personality disorder declines in the short and midterms, but is relatively stable in the longer term. For example, 97%reported participating in individual therapy at study entry and this rate declined significantly to 73% at eight-year follow-up. However, this 73% only declined to 65% at 16-year follow-up. This same pattern was also found, for another example, with any standing medication. More specifically, 84% of patients with borderline personality disorder reporting taking a standing medication at study entry and this rate declined significantly to 71% over the first eight years of follow-up. However, this rate remained a steady 71% over the second eight years of follow-up. As a third example, 79% of patients with borderline personality disorder had a history of prior hospitalizations at baseline and the rate of hospitalizations declined significantly to 28% at eight-year follow-up. However, this 28% rate only declined to 24% by the time of the 16-year follow-up.

While the rates of these three major treatment modalities have substantially declined for patients with borderline personality disorder over time, the fact that they have barely declined in the second eight years of follow-up suggests that these may be chronic rates of treatment going forward. The good news in terms of cost is the relatively low rate of psychiatric hospitalizations at 16-year follow-up (24%). In a similar vein, only 15% of patients with borderline personality disorder had multiple hospitalizations, while only 4% spent 30 days or more in a psychiatric inpatient unit.

However, the question remains if these rates will remain stable going forward or if there is anything clinicians or the health care system can do or would want to do to lower these rates further. It may be that these rates at 16-year follow-up of individual therapy (65%) and standing medication (71%) are helping patients with borderline personality disorder stay out of the hospital. And the rate of more costly forms of these outpatient modalities has also dropped. More specifically, the rate of intensive individual therapy dropped from 36% to 13%, and the rate of aggressive polypharmacy (three or more concurrent medications) dropped from 46% to 36%.

However, the relatively high percentages of patients who reported that they were using individual therapy and standing medications over the second eight years of follow-up is striking, particularly given the high rates of sustained remissions found over the 16 years of follow-up (16). For example, 99% of patients with borderline personality disorder reported a two-year remission, 95% reported a four-year remission, and 90% reported a six-year remission. It may be that these patients were dealing with residual symptoms of borderline personality disorder, particularly the less dramatic or temperamental symptoms (e.g., anxiety, abandonment concerns, undue dependency) that have been found to resolve more slowly than the acute symptoms of this disorder (e.g. self-harm, suicide attempts, quasi-psychotic thought) (17). It may also be that these patients were being treated for axis I disorders that had never remitted or recurred (18).

The main limitation of this study is that all of the patients with borderline personality disorder were severely ill inpatients at the time of study entry. The rates of treatment use might be substantially lower for those with borderline personality disorder who have never been hospitalized and/or never been in psychiatric treatment. This same limitation applies to axis II comparison participants as well. In addition, reported rates of many forms of more intensive treatments (e.g., residential treatment, 30 days or more of psychiatric hospitalization) were very low for axis II comparison subjects during the last eight years of follow-up; consequently, due to sparseness of data, extra caution is required when interpreting results from our regression analyses for these particular treatments.

It is worth noting that most study participants were treated in the community. Psychotherapy was mostly provided by hundreds of community-based psychologists and social workers located throughout the US. In addition, these therapies were mostly supportive in nature and almost none were empirically based (20-24). Medications were prescribed by psychiatrists in general practice or, increasingly, by primary care physicians.

Acknowledgments

Supported by NIMH grants MH47588 and MH62169.

References

  • 1.Skodol AE, Buckley P, Charles E. Is there a characteristic pattern to the treatment history of clinic outpatients with borderline personality? Journal of Nervous and Mental Disorders. 1983;171:405–410. doi: 10.1097/00005053-198307000-00003. [DOI] [PubMed] [Google Scholar]
  • 2.Perry JC, Cooper SH. In: Psychodynamics, symptoms, and outcome in borderline and antisocial personality disorders and bipolar type II affective disorder; in The Borderline: Current Empirical Research. McGlashan TH, editor. Washington, DC: American Psychiatric Press; 1985. [Google Scholar]
  • 3.Swartz M, Blazer D, George L, et al. Estimating the prevalence of borderline personality disorder in the community. Journal of Personality Disorders. 1990;4:252–272. [Google Scholar]
  • 4.Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. American Journal of Psychiatry. 2001;158:295–302. doi: 10.1176/appi.ajp.158.2.295. [DOI] [PubMed] [Google Scholar]
  • 5.Zanarini MC, Frankenburg FR, Khera GS, et al. Treatment histories of borderline inpatients. Comprehensive Psychiatry. 2001;42:144–150. doi: 10.1053/comp.2001.19749. [DOI] [PubMed] [Google Scholar]
  • 6.Bender DS, Skodol AE, Pagano ME, et al. Prospective assessment of treatment use by patients with personality disorders. Psychiatric Services. 2006;57:254–257. doi: 10.1176/appi.ps.57.2.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zanarini MC, Frankenburg FR, Hennen J, et al. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. Journal of Clinical Psychiatry. 2004;65:28–36. doi: 10.4088/jcp.v65n0105. [DOI] [PubMed] [Google Scholar]
  • 8.Hörz S, Zanarini MC, Frankenburg FR, et al. Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders. Psychiatric Services. 2010;61:612–616. doi: 10.1176/appi.ps.61.6.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zanarini MC, Frankenburg FR, Hennen J, et al. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. American Journal of Psychiatry. 2003;160:274–283. doi: 10.1176/appi.ajp.160.2.274. [DOI] [PubMed] [Google Scholar]
  • 10.Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Archives of General Psychiatry. 1992;49:624–629. doi: 10.1001/archpsyc.1992.01820080032005. [DOI] [PubMed] [Google Scholar]
  • 11.Zanarini MC, Gunderson J, Frankenburg FR, et al. The Revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders. Journal of Personality Disorders. 1989;3:10–18. [Google Scholar]
  • 12.Zanarini MC, Frankenburg FR, Chauncey DL, et al. The Diagnostic Interview for Personality Disorders: interrater and test-retest reliability. Comprehensive Psychiatry. 1987;28:467–480. doi: 10.1016/0010-440x(87)90012-5. [DOI] [PubMed] [Google Scholar]
  • 13.Zanarini MC, Frankenburg FR. Attainment and maintenance of reliability of axis I and II disorders over the course of a longitudinal study. Comprehensive Psychiatry. 2001;42:369–374. doi: 10.1053/comp.2001.24556. [DOI] [PubMed] [Google Scholar]
  • 14.Zanarini MC, Frankenburg FR, Vujanovic AA. Inter-rater and test-retest reliability of the Revised Diagnostic Interview for Borderlines. Journal of Personality Disorders. 2002;16:270–276. doi: 10.1521/pedi.16.3.270.22538. [DOI] [PubMed] [Google Scholar]
  • 15.Zanarini MC. Revised Borderline Follow-up Interview. McLean Hospital; Belmont, MA: 1994. [Google Scholar]
  • 16.Zanarini MC, Frankenburg FR, Reich DB, et al. Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study. American Journal of Psychiatry. 2012;169:476–83. doi: 10.1176/appi.ajp.2011.11101550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zanarini MC, Frankenburg FR, Reich DB, et al. The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. American Journal of Psychiatry. 2007;164:929–35. doi: 10.1176/ajp.2007.164.6.929. [DOI] [PubMed] [Google Scholar]
  • 18.Zanarini MC, Frankenburg FR, Hennen J, et al. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. American Journal of Psychiatry. 2004;161:2108–2114. doi: 10.1176/appi.ajp.161.11.2108. [DOI] [PubMed] [Google Scholar]
  • 19.Zanarini MC, Frankenburg FR, Vujanovic AA, et al. Axis II comorbidity of borderline personality disorder: description of 6-year course and prediction to time-to-remission. Acta Psychiatrica Scandinavica. 2004;110:416–420. doi: 10.1111/j.1600-0447.2004.00362.x. [DOI] [PubMed] [Google Scholar]
  • 20.Linehan MM, Armstrong HE, Suarez A, et al. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry. 1991;48:1060–1064. doi: 10.1001/archpsyc.1991.01810360024003. [DOI] [PubMed] [Google Scholar]
  • 21.Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry. 1999;156:1563–1569. doi: 10.1176/ajp.156.10.1563. [DOI] [PubMed] [Google Scholar]
  • 22.Giesen-Bloo J, van Dyck R, Spinhoven P, et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs. transference-focused psychotherapy. Archives of General Psychiatry. 2006;63:649–658. doi: 10.1001/archpsyc.63.6.649. [DOI] [PubMed] [Google Scholar]
  • 23.Clarkin JF, Levy KN, Lenzenweger MF, et al. Evaluating three treatments for borderline personality disorder: a multiwave study. American Journal of Psychiatry. 2007;164:922–928. doi: 10.1176/ajp.2007.164.6.922. [DOI] [PubMed] [Google Scholar]
  • 24.McMain SF, Links PS, Gnam WH, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. American Journal of Psychiatry. 2009;166:1365–1374. doi: 10.1176/appi.ajp.2009.09010039. [DOI] [PubMed] [Google Scholar]

RESOURCES